Quick Facts

• Motion Sickness: Used for the prevention and symptomatic management of nausea, vomiting, and dizziness associated with motion sickness.
• Vertigo: Utilized for the management of dizziness (vertigo) caused by conditions that affect the inner ear's vestibular system.

Бонин (Meclizine) is a medication utilized to address specific symptoms related to motion and balance. The medication’s main uses are centered on providing symptomatic relief and preventative action. It may be considered for the management of nausea, vomiting, and dizziness, which are common manifestations of motion sickness. For this purpose, it can be taken before travel to support a reduction in anticipated symptoms.

Furthermore, the drug is indicated for the management of vertigo, a sensation of spinning or dizziness, particularly when associated with diseases affecting the vestibular system. This therapeutic application requires a healthcare professional’s assessment to determine suitability and proper use.

Eligibility Map: Who can and cannot use Бонин?

The official regulatory documents define the eligible population for Meclizine hydrochloride, known commercially as Бонин, through strict rules concerning age, pre-existing conditions, and physical status.

Populations with Eligibility Restrictions

Contraindicated Populations: Individuals must not use this medicine if they have a known hypersensitivity to Meclizine hydrochloride or any of its inactive ingredients.

Age-Related Eligibility: Use is established and allowed for adults and adolescents 12 years of age and older. Use is not recommended for children younger than 12 years because safety and effectiveness have not been formally established in this age group. Elderly patients require cautious administration due to the general decline in hepatic and renal function with age.

Conditional Use Restrictions: The medicine should be administered with caution to patients with certain pre-existing conditions, due to its potential anticholinergic effects. These conditions include Asthma, Glaucoma, and enlargement of the prostate gland. Caution is also required for patients with hepatic impairment or renal impairment due to the potential for drug accumulation.

Pregnancy and Lactation Status: Regulatory classification advises that use during pregnancy should occur only if clearly necessary. For nursing mothers, caution should be exercised as it is not known whether the medicine is excreted in human milk.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Meclizine (Бонин) as reported in government regulatory documents.

---

Pharmacodynamic and Substance Interactions

Co-administration with other Central Nervous System (CNS) depressants, including tranquilizers and sedatives, may lead to increased CNS depression. This pharmacodynamic reinforcement extends to the consumption of alcoholic beverages, which patients must avoid due to the potential for a severe additive depressant effect. Additionally, Monoaminooxidase (MAO) inhibitors may prolong and intensify the anticholinergic effects of meclizine, as documented in some regulatory monographs.

---

Pharmacokinetic and Exposure Constraints

Meclizine is metabolized via the CYP2D6 enzyme system. Accordingly, a possibility for a drug interaction exists when Meclizine is co-administered with CYP2D6 inhibitors, which may alter the drug's metabolism and exposure.

Regulatory cautions tied to the drug's clearance profile note that pre-existing hepatic impairment may result in increased systemic exposure. Similarly, caution is required for individuals with renal impairment or who are elderly due to a potential for drug or metabolite accumulation stemming from the excretion pathway.

---

Interaction Restrictions

The most prominent interaction-related constraint is the formal requirement to avoid alcoholic beverages. Furthermore, the drug is formally contraindicated in individuals with known hypersensitivity to meclizine hydrochloride or any of its inactive ingredients.

Dual Central Neurotransmitter Blockade

The molecule's primary action is defined by a simultaneous competitive antagonism at central histamine H1 receptors and a significant anticholinergic action at central muscarinic receptors. This dual antagonism blocks the excitatory signaling of both histamine and acetylcholine within the brainstem, specifically disrupting neurotransmission within the vestibular nuclei and associated emetic pathways.

---

Suppression of Vestibular and Emesis Pathways

Receptor antagonism leads to the central physiological suppression of neural impulse transmission within the pathways originating from the inner ear's vestibular system, resulting in decreased excitability within the vestibular nuclei. This mechanism further reduces the sensitivity of the medullary vomiting center and the chemoreceptor trigger zone (CTZ). The resulting physiological effect is the reduction of afferent signaling to the higher centers of motion integration.

---

Mechanistic Constraints and Adaptive Limits

The central depressant mechanism is dependent on its capacity to cross the blood-brain barrier; the resulting physiological effect may be functionally constrained during high-intensity acceleratory stimuli. Furthermore, sustained central depression may inhibit the long-term process of central vestibular compensation, which is the brain's physiological mechanism for restoring reflex function following vestibular insult.

Бонин is the trade name for the active ingredient Meclizine, which is designed strictly for oral administration. The official usage is defined by distinct administration patterns based on the intended context, requiring different dosing and frequency schedules.

Official Dosing and Frequency

For the prevention of motion sickness, the official initial dose is typically 25 mg to 50 mg. This single dose is structured to be taken approximately one hour before starting travel. This dose may be repeated every 24 hours for continued use throughout the duration of the journey.

The administration pattern for the management of vertigo differs significantly. The prescribed total daily dosage ranges from 25 mg to 100 mg, and this total amount is administered in divided doses throughout the day.

Administration Requirements

Proper administration also depends on the dosage form. The chewable tablet form must be chewed or crushed completely prior to swallowing; it is not designed to be swallowed whole. Conversely, the non-chewable tablet form is intended to be swallowed whole.

Population-Specific Guidance

Specific limitations and cautions exist for certain populations. The drug is not recommended for children under 12 years of age as safety and efficacy have not been established. For older adults, dose selection should proceed with caution, typically initiating treatment at the low end of the established dosing range.

Research Evidence Overview for Бонин (Meclizine)

Evidence for Use in Motion Sickness

Research was studied for exploring symptoms associated with motion sickness, which is a condition involving nausea, vomiting, and dizziness when traveling. This use was studied for both prevention, which involves administration prior to exposure, and for observing symptom change during an episode.

The primary research approach was observed in short-term Randomized Controlled Trials (RCTs) and controlled human laboratory studies. The study populations mainly included healthy adult volunteers and adults known to be susceptible to motion sickness, with research often observing responses over defined time intervals (e.g., during motion exposure).

Findings from the studies describe patterns observed in the populations, and the evidence level for this application is often classified as Moderate. Research highlights that findings were mixed when compared to other study agents, and results show patterns related to different comparative performances.

Evidence for Use in Vertigo and Vestibular Dizziness

The use of Meclizine was evaluated in conditions of dizziness (vertigo) stemming from inner ear or vestibular system disturbances. Research for this application was based on a different body of work, including observational cohort studies from clinical settings and older, smaller comparative trials.

Studies examined outcomes related to systemic or functional imbalance, such as the patient-reported intensity of vertigo. The populations observed in the studies included adult patients presenting with acute dizziness. The evidence level for this use is generally described as Low to Moderate.

Long-Term Studies and Follow-Up Duration

For both motion sickness and acute vertigo, the research exploring short-term symptom changes was observed in studies where the follow-up durations were limited. Most trials and observational periods for acute use are focused on immediate or short-term outcomes. As a result, there is limited information for long-term outcomes regarding the use of Meclizine. Evidence contributes to the broader evidence landscape but generally provides limited information on the durability of response or long-term functional outcomes.

Understanding the Strength and Gaps in the Research

The evidence level is classified as Moderate for motion sickness and Low to Moderate for acute vertigo. Key areas where research remains uncertain and where evidence is limited include long-term effects. Chronic use may be associated with outcomes related to systemic or functional imbalance (vestibular compensation). Subgroup findings are uncertain due to modest sample sizes, and data for certain groups remain insufficient, particularly for children under 12.

Key Studies & References

1. Meclizine
2. Meclizine - StatPearls

Common questions about Бонин (FAQ)

Q: Can Bonin cause sleep problems?

Official product information describes drowsiness and fatigue as common adverse reactions associated with the use of this medicine. Reporting any unexpected or severe changes in sleep patterns to a healthcare professional is consistent with general guidance for all medications.

---

Q: Does Bonin have a long-lasting effect after stopping treatment?

The duration of the therapeutic effect is generally described as being between 8 and 24 hours. The medicine's active ingredient, meclizine, has a plasma elimination half-life of approximately 5 to 6 hours, meaning the effects are not considered long-lasting after the drug is fully cleared from the body.

---

Q: How might Bonin affect blood pressure?

While low blood pressure (hypotension) is not listed as a common side effect in official documents, it has been documented as a possible effect in cases of serious adverse events or overdose. Official warnings prioritize the potential for severe additive depressant effects when the medicine is taken with other central nervous system (CNS) depressants or alcohol.

---

Q: Why is caution required for Bonin use in people with glaucoma?

Regulatory documents state that caution is required because the medicine possesses an anticholinergic action. This specific pharmacological property may potentially worsen conditions like glaucoma. This warning is included to inform patients of potential risks associated with the drug’s properties under this condition.

---

Q: Are there specific safety considerations for older adults taking Bonin?

Official warnings note that older adults may be more susceptible to certain side effects, including drowsiness and confusion. Regulatory documents indicate that dose selection for older adults typically involves starting at the low end of the established range due to the generally greater frequency of decreased organ function in this population.

---

Q: Are there general restrictions concerning Bonin and chronic health conditions?

Official documents advise caution in patients with specific chronic conditions due to the medicine's properties. These conditions include asthma, glaucoma, or enlargement of the prostate gland, as well as pre-existing hepatic (liver) or renal (kidney) impairment.

---

Q: What should be done if a scheduled dose of Bonin is missed?

General guidance for the administration of this medicine is to avoid doubling the dose to compensate for the missed amount. Instead, the next dose should be taken at its regularly scheduled time.

---

Q: Is it necessary to take Bonin with food?

The official product information indicates that the medicine may be taken with or without food, as its administration is not dependent on mealtime. This allows for flexibility in when the dose is ingested.

---

Q: How quickly does Bonin start working?

According to pharmacologic data provided in official sources, the onset of action for the medicine occurs approximately one hour after it is taken by mouth.

---

Q: How long does Bonin remain in the body?

The active ingredient, meclizine, is processed by the body and has a plasma elimination half-life of approximately 5 to 6 hours in humans. This half-life is used by regulatory bodies to understand the drug's overall clearance profile.

---

Q: Does Bonin accumulate in the body over time?

While the medicine generally clears from the body, official regulatory warnings note a risk of the drug or its metabolites accumulating in individuals with pre-existing hepatic (liver) or renal (kidney) impairment. This caution is in place due to their potential for altered drug clearance.

---

Q: Can Bonin interfere with diagnostic tests?

Official documents note that the coadministration of antihistamines may alter diagnostic results related to certain types of skin tests. This potential for interference is an important factor to consider before diagnostic procedures are performed.

---

Q: Why might Bonin not be effective for some individuals?

Official regulatory documents note that there is large inter-individual variability in how a person's body processes the medicine. This variation in drug exposure can potentially influence the clinical response observed by the patient.

---

Q: What are the risks of an accidental overdose of Bonin?

An overdose is considered a serious medical event and is managed by seeking immediate medical attention. Documented symptoms of overdose may include severe drowsiness, confusion, or hallucinations.

---

Q: Does Bonin interact with herbal supplements?

Caution is advised when taking this medicine with herbal supplements that may have sedative effects (calming or sleep-inducing). Combining such substances could increase the risk of side effects like drowsiness and dizziness.

---

Q: Are there any dietary restrictions when taking Bonin?

The primary warning related to ingestion is the formal constraint that alcoholic beverages must be avoided while using the medicine. This is because alcohol may intensify the drug's central nervous system depressant effects.

---

Q: What types of studies contribute to Bonin's safety information?

Information regarding the safety profile is compiled during clinical studies conducted before approval. Additionally, data continues to be gathered through post-marketing reports of adverse events, which are essential for long-term safety monitoring.

---

Q: Is Bonin classified as a narcotic or psychotropic substance?

This medicine is classified as an antihistamine and an antiemetic agent. According to current regulatory classifications, it is not scheduled as a controlled substance under the U.S. Controlled Substances Act (CSA).

---

Q: Is Bonin associated with the risk of addiction?

Because the medicine is not categorized as a controlled substance by regulatory bodies, it is not generally associated with the risk of addiction in official documents.

---

Q: What are the general official expectations regarding the effectiveness of Bonin treatment?

The drug is officially classified as effective for the prevention and treatment of symptoms associated with motion sickness (such as nausea and vomiting). It is also classified as possibly effective for managing vertigo that results from diseases of the vestibular system.

---

Q: Why do official sources include restrictions and warnings for Bonin?

Restrictions and warnings are included in official documents to manage the known risks and potential adverse effects, such as the drug's anticholinergic action. This practice is designed to promote the safest possible use across the authorized patient population.

---

Q: Does Bonin affect mood or emotional state?

While generally uncommon, post-marketing reports have documented rare instances of mental or mood changes. These changes may include effects such as restlessness or confusion.

---

Q: Can the Bonin tablet be split in half?

The official administration requirements specify that the chewable tablet form must be fully chewed or crushed before swallowing. Conversely, the non-chewable tablet form is intended to be swallowed whole.

---

Q: Why is caution sometimes advised regarding Bonin, particularly in older adults?

Authoritative geriatric guidelines, such as the Beers Criteria, suggest caution regarding this medicine in older patients. This is primarily due to its anticholinergic properties, which may increase the risk of adverse outcomes like confusion and falls in this population.

Storage and Disposal Instructions for Bonine (Meclizine Hydrochloride)

Bonine must be stored under specific conditions to maintain its stability and effectiveness, as mandated by regulatory documentation.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection	The medication must be protected from excessive heat and humidity.
Container	Keep the product in a tightly closed container.
Safety	The medicine must be kept out of the sight and reach of children.

---

Disposal of Unused Product

If Bonine is expired or no longer needed, it must be disposed of correctly. Regulatory guidelines state that meclizine is not on the list of medicines recommended for flushing down the toilet. Disposal should follow the standard procedure for non-flushable medications, typically involving mixing the product with an unappealing substance and sealing it before placing it in household trash.